Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
ELEVATE-HFpEF Clinical Study
NCT06678841 · View on ClinicalTrials.gov ↗
Study Summary
ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
Conditions Studied
Interventions
- DEVICE Personalized cardiac pacing
Study Locations (20)
Other
- Ordensklinikum Linz GmbH / Elisabethinen — Linz
- Universitair Ziekenhuis Antwerpen — Edegem
- Centre Hospitalier Universitaire Besancon - Hôpital Jean Minjoz — Besançon
Ohio
- The Ohio State University Wexner Medical Center — Columbus
- Mount Carmel East — Columbus
Connecticut
- Hartford Hospital — Hartford
Florida
- Cardiovascular Institute of Northwest Florida — Panama City
Georgia
- Emory University — Atlanta
Iowa
- Iowa Heart Center — Des Moines
Louisiana
- Cardiovascular Institute of the South — Houma
Missouri
- Saint Lukes Mid America Heart Institute — Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2029-02 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06678841
The ClinicalTrials.gov registry entry for NCT06678841 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 56 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction (HFpEF) appearing as the primary indexed condition, and to 1 intervention — of which Personalized cardiac pacing is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06678841 reports 20 study locations spanning 17 distinct geographic areas — top geographies include Other, Ohio, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06678841 about?
NCT06678841 is a clinical study titled "ELEVATE-HFpEF Clinical Study". ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection ...
What is the current status of trial NCT06678841?
This trial is currently recruiting. It is a NA study. The enrollment target is 700 participants. The study started on 2025-07-09. Estimated completion is 2029-02.
What conditions does trial NCT06678841 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFpEF). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06678841?
The interventions under investigation include: Personalized cardiac pacing (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06678841?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 56 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06678841 being conducted?
This trial has 20 study locations across Connecticut, Florida, Georgia, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.